AEB071 + Everolimus
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Conditions
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Trial Timeline
Dec 5, 2013 → Jun 1, 2016
NCT ID
NCT01854606About AEB071 + Everolimus
AEB071 + Everolimus is a phase 1 stage product being developed by Novartis for CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01854606. Target conditions include CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01854606 | Phase 1 | Completed |